General Information

Information for Healthcare Professionals

MIMS Ireland, or Monthly Index of Medical Specialities Ireland, is an independently edited publication designed as a drug prescribing guide for the general practitioner. It is a comprehensive and up-to-date index of both prescription and over-the-counter medicines licensed for use in Ireland, and it has been updated and published monthly since 1960.

New Products, New Presentations, New This month

New Products, New Presentations, New This month

Each month an extended monograph of products and presentations that have recently been launched on the Irish market is included at the front of MIMS Ireland.

Drugs can be included in MIMS Ireland if they have a Product Authorisation number (PA number) and therefore have an SPC, or unlicensed drugs that are GMS/HT reimbursable. In addition to branded products, MIMS Ireland also includes  information on branded generic drugs (prescribing information and prices) and true generic drugs (prices).

The information published is based upon details included in the Summary of Product Characteristics (SPC) or supplied by the manufacturers. A more abbreviated prescribing information of the products (regular monographs) is included in the main body of the book.

New packaging, dosage and indication changes, reformulations and other news of interest to the GP are featured in the New This Month section which follows the New Products and New Presentations sections.

New Clinical Evidence

New Clinical Evidence

This section features an independent editorial review of clinical trials recently published in peer reviewed journals or presented at international congresses. The clinical trial results usually highlight new data on a particular drug, or a head to head comparison between two drugs.

Clinical Specials

Clinical Specials

A monthly focus on a particular condition or area is included in the Clinical Special section or in a separate Supplement. This summarises recent international guidelines and usually include tables or flow charts designed to guide doctors with an easy to read step-to-step approach. See the list of topics for all Clinical Specials and MIMS Ireland Supplements outlined for 2017 (this schedule is subject to change).

Health Products Regulatory Authority

Health Products Regulatory Authority

This section includes a monthly update from the Health Products Regulatory Authority (HPRA). The HPRA monitors the safety of authorised medicinal products for human use available on the Irish market, on an on-going basis. Part of this monitoring is carried out through review and evaluation of suspected adverse reactions and the HPRA encourages all healthcare professionals to notify suspected adverse reactions observed during their practice. Any centres or practices wishing to develop their reporting systems should contact the HPRA Pharmacovigilance Section (telephone 01-6764971, fax 01-6762517, e-mail medsafety@hpra.ie).

Post-paid adverse reaction report forms are available on request from the Pharmacovigilance Section of the HPRA (contact details above). A downloadable version of the report form is also available from the ‘Report an Issue’ area of the HPRA website www.hpra.ie. These may be completed and forwarded in an envelope marked Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Centre, Earlsfort Terrace, Dublin 2.

Sport Ireland

Sport Ireland

A one-page summary of the World Anti-Doping Agency (WADA) Code is featured in the preliminary pages section before the Prescription Products. This page is updated every year, as the WADA issues a new Prohibited List of Substances and Methods which comes into effect on January of each year. Changes to the Prohibited List are as a result of ongoing reviews by the WADA List and Medical and Research Committees.

A substance or method is added to the List if it meets two of three criteria: It is performance enhancing, poses a danger to athletes’ health and its use is against the spirit of sport.

Prescription Products

Prescription Products

The main part of the book includes up-to-date prescribing information of medicinal products available on the Irish market. The information is based upon details included in the Summary of Product Characteristics (SPC) or supplied by the manufacturers. The drug monographs are deliberately concise, so readers are strongly advised to refer to the SPC when full details and the clinical significance of the products’ contraindications, special precautions, drug interactions, adverse reactions or overdose are required.

Prices

Prices

The Price to Wholesalers (PTW) is given for the following products: GMS-reimbursed products, products on the High-Tech scheme and Hospital-only products. The reimbursement price is given for nutritional products. The trade price is given for all other products. None of these prices include pharmacist dispensing fees. Prices are quoted to enable the prescriber to compare the cost of proprietary preparations and do not have any relation to the retail cost of the drug, nor of its cost if obtained on a private prescription.

Excipients

Excipients

Many products contain additional ingredients to those active constituents included in this index (e.g. lanolin, sucrose etc.). These may cause unwanted effects in some patients. Manufacturers should be consulted where the full formulation of a drug is required.

Appendix I

Appendix I

Appendix I includes a list of substrates, inducers or inhibitors of cytochrome P450 CYP3A4 isoform. This list can be used to assess possible interactions between medicinal products interacting with P450 CYP3A4 – e.g. CYP3A4 inhibitors and inducers interact with CYP3A4 substrates; CYP3A4 substrates compete with each other. Depending on the type of interaction, and whether the active substance is the actual drug or its metabolite, the effect of the medicinal product will be enhanced or reduced.

Manufacturers' Index

Manufacturers' Index

Addresses and telephone numbers of pharmaceutical companies whose products are listed in MIMS Ireland.

Interchangeable Medicines and Reference Pricing

Interchangeable Medicines and Reference Pricing

This section contains a table of all active ingredients on the interchangeable medicines list, their strength, pharmaceutical form, and route of administration. It also includes reference prices for selected groups of medicines, where they have been introduced. Medicines which can be substituted by another medicine on this list are denoted by the interchangeable medicines symbol in their product monographs throughout the MIMS Ireland publication. For more information on interchangeable medicines and their reference prices, please see the relevant section of this website.

Prescribing Notes

Prescribing Notes

Prescribing Notes (in green) are included throughout the book and include information on various conditions and treatment options available. Drug Prescribing Notes include prescribing information on one particular class of drugs or a particular active ingredient. Anti-doping information (in yellow) includes information related to the use of drugs in sport. Remaining pink boxes include more general information (e.g. symbols used, MIMS Ireland policy).

Alphabetical Index

Alphabetical Index

Combined alphabetical and non-proprietary index incorporating a page reference for all products, a cross index to their generic ingredients and a section reference for medical conditions.

Information for Pharmaceutical Companies

Product inclusion

Product inclusion

Drugs can be included in MIMS Ireland if they have a Product Authorisation number (PA number) and therefore have an SPC, or unlicensed drugs that are GMS/HT reimbursable. In addition to branded products, MIMS Ireland also includes  information on branded generic drugs (prescribing information and prices) and true generic drugs (prices).

Pricing

Pricing

Following changes introduced by the HSE for the reimbursement of medicines under the various HSE community schemes, and as MIMS Ireland relies on manufacturers for the prices published with entries, the pricing policy of MIMS Ireland has changed. Our current pricing policy is as follows:

  • The Price To Wholesalers (PTW) is given for GMS-reimbursed products, products on the High-Tech scheme and hospital-only products.
  • The reimbursement price is given for nutritional products.
  • The trade price is given for all other products.

Deadlines for material submission

Deadlines for material submission

The 2017 deadlines for material submission (at least the SPC) for MIMS Ireland Main Book and Supplements are:

Issue Deadlines for Material Submission
Feb-17 Wednesday, 11th January 2017
Mar-17 Wednesday, 8th February 2017
Apr-17 Friday, 10th March 2017
May-17 Thursday, 6th April 2017
Jun-17 Wednesday, 10th May 2017
Jul-17 Monday, 12th June 2017
Aug-17 Tuesday, 11th July 2017
Sep-17 Thursday, 10th August 2017
Oct-17 Monday, 11th September 2017
Nov-17 Tuesday, 10th October 2017
Dec-17 Friday, 10th November 2017
Jan-18 Tuesday, 5th December 2017

How to enter your New Product or New Presentation

How to enter your New Product or New Presentation

To place a new product or presentation in MIMS Ireland, the editorial team requires the following information:

  1. The SPC (preferably electronically).
  2. The Irish price – The price to wholesale (PTW) for GMS-reimbursed products, products on the High-Tech scheme and hospital-only products; the trade price for all other products – and pack size.
  3. GMS/HT status: Whether the product is reimbursable under the GMS or HT scheme.
  4. Legal category: S1A (prescribed once only unless the prescriber specifically states that it can be dispensed on more than one occasion), S1B (may be repeated for up to six months from the date of issue, unless the prescriber specifically limits the number of repeats or the amount to be dispensed) and/or hospital only.
  5. If a product is not on prescription is it a Pharmacy Only or an Over-the-Counter product.
  6. Contact details (Telephone, Fax, Email address) you would like to be included.

How to update a MIMS Ireland entry

How to update a MIMS Ireland entry

The editorial team ask that they are notified of all changes that may affect a MIMS Ireland entry.

  • To update an entry please provide us with details of the change and an SPC with tracked changes (if available) or the updated SPC.
  • Other changes that will affect a MIMS Ireland entry include changes of price, manufacturer, and pack size.

How to include information in the New This Month section

How to include information in the New This Month section

In the New This Month section we include press releases regarding

  • A new indication
  • New packaging
  • A new name
  • New Marketing Authorisation Holders
  • And anything else that is deemed suitable to include here.

If you would like us to include a press release regarding any of the above you may provide us with a press release of approximately 150 words.

Discontinued Products

Discontinued Products

Every month we provide an updated list of products withdrawn in Ireland in the last 12 months. Please inform us of any product/presentation discontinuations.

How to include a New Clinical Evidence article

How to include a New Clinical Evidence article

A New Clinical Evidence article consists of an independent editorial review of clinical trials recently published in peer reviewed journals or presented at international congresses. The clinical trial results usually highlight new data on a particular drug, or a head to head comparison between two drugs. Companies are invited to submit any new data they would like to highlight before the editorial deadline (please contact the Editor for information on deadlines). If the new data happen to be in relation to the Feature topic of the month, they will be included in the Clinical Special Section; any other data will be included in the New Clinical Evidence section.

The New Clinical Evidence piece is written by our editorial team and includes a packshot and a logo provided by the company. The company is usually also asked to provide a press release along with the original material (published article, abstract, or poster).

For more information on related costs, please contact Advertising.

How to include information in the Clinical Special section

How to include information in the Clinical Special section

A monthly focus on a particular condition or area is included in a Clinical Special section or in a separate Supplement. The information provided is normally designed to give an overview of recent international or national guidelines and usually include tables or flow charts aimed at guiding doctors with an easy to read step to step approach. Companies are invited to submit any ideas or materials which are relevant for the topic of the month. The editorial team can write up the piece or alternatively include guidelines/flow charts/tables directly provided by the companies.
See the list of topics for all Clinical Specials and MIMS Ireland Supplements outlined for 2017 (this schedule is subject to change).
For more information, including sponsorship costs, please contact Advertising.

Health Products Regulatory Authority

Health Products Regulatory Authority

This section of MIMS Ireland includes a monthly update from the Health Products Regulatory Authority (HPRA). The HPRA monitors the safety of authorised medicinal products for human use available on the Irish market, on an on-going basis. Part of this monitoring is carried out through review and evaluation of suspected adverse reactions. Post-paid adverse reaction report forms are available on request from the Pharmacovigilance Section of the HPRA (telephone 01-6764971, fax 01-6762517, e-mail medsafety@hpra.ie). A downloadable version of the report form is also available from the ‘Report an Issue’ area of the HPRA website www.hpra.ie. These may be completed and forwarded in an envelope marked Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Centre, Earlsfort Terrace, Dublin 2.
See the entry on this website regarding the Health Products Regulatory Authority.

Sport Ireland

Sport Ireland

A one-page summary of the World Anti-Doping Agency (WADA) Code is included in the Prelims Section before the Prescription Products. This page is updated every year, as the WADA issues a new Prohibited List of Substances and Methods which comes into effect on January of each year. The company does not need to provide this information as the sport category of any given medicinal product is given to MIMS Ireland by Sport Ireland.